Sagimet Current Deferred Revenue vs Net Invested Capital Analysis

SGMT Stock

5.36 0.33 5.80%

Sagimet Biosciences financial indicator trend analysis is much more than just breaking down Sagimet Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sagimet Biosciences is a good investment. Please check the relationship between Sagimet Biosciences Current Deferred Revenue and its Net Invested Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sagimet Biosciences Series. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Current Deferred Revenue vs Net Invested Capital

Current Deferred Revenue vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sagimet Biosciences Current Deferred Revenue account and Net Invested Capital. At this time, the significance of the direction appears to have strong relationship.

The correlation between Sagimet Biosciences' Current Deferred Revenue and Net Invested Capital is 0.64. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Sagimet Biosciences Series, assuming nothing else is changed. The correlation between historical values of Sagimet Biosciences' Current Deferred Revenue and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Sagimet Biosciences Series are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Current Deferred Revenue i.e., Sagimet Biosciences' Current Deferred Revenue and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.64

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from Sagimet Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sagimet Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sagimet Biosciences Series. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At this time, Sagimet Biosciences' Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.63 in 2024, despite the fact that Enterprise Value is likely to grow to (17.5 M).

	2021	2022	2023	2024 (projected)
Interest Income	26K	553K	1.7M	1.8M
Net Interest Income	26K	553K	1.7M	1.8M

Interest Income Net Interest Income

Sagimet Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		-0.82	0.77	0.65	0.61	-0.38	-0.81	-0.93	-0.78	-0.94	0.94	-0.8	-0.58	-0.58	1.0	-0.75	-0.31	-0.82	0.79	0.9	-0.3	0.61	-0.81	1.0	0.74	1.0
Short Long Term Debt Total	-0.82		-0.85	-0.8	-0.81	0.16	1.0	0.75	0.92	0.9	-0.66	1.0	0.84	0.84	-0.82	0.85	0.61	1.0	-0.53	-0.7	0.6	-0.81	1.0	-0.82	-0.78	-0.81
Other Current Liab	0.77	-0.85		0.98	0.6	-0.19	-0.83	-0.54	-0.9	-0.69	0.52	-0.83	-0.58	-0.58	0.77	-0.8	-0.41	-0.85	0.67	0.45	-0.39	0.6	-0.83	0.77	0.8	0.75
Total Current Liabilities	0.65	-0.8	0.98		0.54	-0.16	-0.77	-0.4	-0.88	-0.58	0.37	-0.77	-0.55	-0.55	0.65	-0.74	-0.39	-0.8	0.59	0.3	-0.37	0.54	-0.77	0.65	0.74	0.62
Total Stockholder Equity	0.61	-0.81	0.6	0.54		0.34	-0.82	-0.68	-0.74	-0.8	0.57	-0.84	-0.92	-0.92	0.61	-0.93	-0.94	-0.81	0.5	0.61	-0.93	1.0	-0.82	0.61	0.85	0.61
Net Tangible Assets	-0.38	0.16	-0.19	-0.16	0.34		0.13	0.31	0.25	0.25	-0.32	0.1	-0.09	-0.09	-0.39	-0.25	-0.64	0.16	-0.26	-0.35	-0.65	0.34	0.13	-0.38	0.29	-0.39
Property Plant And Equipment Net	-0.81	1.0	-0.83	-0.77	-0.82	0.13		0.75	0.89	0.89	-0.66	1.0	0.84	0.84	-0.81	0.85	0.63	1.0	-0.48	-0.7	0.61	-0.82	1.0	-0.81	-0.78	-0.79
Net Debt	-0.93	0.75	-0.54	-0.4	-0.68	0.31	0.75		0.68	0.96	-0.97	0.75	0.67	0.67	-0.93	0.69	0.4	0.75	-0.72	-0.99	0.39	-0.68	0.75	-0.93	-0.64	-0.94
Retained Earnings	-0.78	0.92	-0.9	-0.88	-0.74	0.25	0.89	0.68		0.83	-0.58	0.9	0.84	0.84	-0.78	0.8	0.53	0.92	-0.72	-0.6	0.52	-0.74	0.89	-0.78	-0.73	-0.76
Accounts Payable	-0.94	0.9	-0.69	-0.58	-0.8	0.25	0.89	0.96	0.83		-0.9	0.89	0.8	0.8	-0.94	0.81	0.53	0.9	-0.7	-0.93	0.52	-0.8	0.89	-0.94	-0.74	-0.94
Cash	0.94	-0.66	0.52	0.37	0.57	-0.32	-0.66	-0.97	-0.58	-0.9		-0.66	-0.5	-0.5	0.94	-0.65	-0.28	-0.66	0.73	0.97	-0.28	0.57	-0.66	0.94	0.64	0.95
Non Current Assets Total	-0.8	1.0	-0.83	-0.77	-0.84	0.1	1.0	0.75	0.9	0.89	-0.66		0.86	0.86	-0.81	0.86	0.65	1.0	-0.5	-0.7	0.64	-0.84	1.0	-0.8	-0.79	-0.79
Non Currrent Assets Other	-0.58	0.84	-0.58	-0.55	-0.92	-0.09	0.84	0.67	0.84	0.8	-0.5	0.86		1.0	-0.58	0.79	0.81	0.84	-0.49	-0.61	0.81	-0.92	0.84	-0.58	-0.66	-0.57
Other Assets	-0.58	0.84	-0.58	-0.55	-0.92	-0.09	0.84	0.67	0.84	0.8	-0.5	0.86	1.0		-0.58	0.79	0.81	0.84	-0.49	-0.61	0.81	-0.92	0.84	-0.58	-0.66	-0.57
Cash And Short Term Investments	1.0	-0.82	0.77	0.65	0.61	-0.39	-0.81	-0.93	-0.78	-0.94	0.94	-0.81	-0.58	-0.58		-0.75	-0.31	-0.82	0.78	0.9	-0.3	0.61	-0.81	1.0	0.74	1.0
Common Stock Shares Outstanding	-0.75	0.85	-0.8	-0.74	-0.93	-0.25	0.85	0.69	0.8	0.81	-0.65	0.86	0.79	0.79	-0.75		0.82	0.85	-0.66	-0.61	0.81	-0.93	0.85	-0.75	-0.98	-0.74
Non Current Liabilities Total	-0.31	0.61	-0.41	-0.39	-0.94	-0.64	0.63	0.4	0.53	0.53	-0.28	0.65	0.81	0.81	-0.31	0.82		0.61	-0.28	-0.33	1.0	-0.94	0.63	-0.31	-0.76	-0.31
Capital Lease Obligations	-0.82	1.0	-0.85	-0.8	-0.81	0.16	1.0	0.75	0.92	0.9	-0.66	1.0	0.84	0.84	-0.82	0.85	0.61		-0.53	-0.7	0.6	-0.81	1.0	-0.82	-0.78	-0.81
Other Current Assets	0.79	-0.53	0.67	0.59	0.5	-0.26	-0.48	-0.72	-0.72	-0.7	0.73	-0.5	-0.49	-0.49	0.78	-0.66	-0.28	-0.53		0.64	-0.27	0.5	-0.48	0.79	0.65	0.78
Other Stockholder Equity	0.9	-0.7	0.45	0.3	0.61	-0.35	-0.7	-0.99	-0.6	-0.93	0.97	-0.7	-0.61	-0.61	0.9	-0.61	-0.33	-0.7	0.64		-0.32	0.61	-0.7	0.9	0.55	0.91
Total Liab	-0.3	0.6	-0.39	-0.37	-0.93	-0.65	0.61	0.39	0.52	0.52	-0.28	0.64	0.81	0.81	-0.3	0.81	1.0	0.6	-0.27	-0.32		-0.93	0.61	-0.3	-0.75	-0.29
Net Invested Capital	0.61	-0.81	0.6	0.54	1.0	0.34	-0.82	-0.68	-0.74	-0.8	0.57	-0.84	-0.92	-0.92	0.61	-0.93	-0.94	-0.81	0.5	0.61	-0.93		-0.82	0.61	0.85	0.61
Property Plant And Equipment Gross	-0.81	1.0	-0.83	-0.77	-0.82	0.13	1.0	0.75	0.89	0.89	-0.66	1.0	0.84	0.84	-0.81	0.85	0.63	1.0	-0.48	-0.7	0.61	-0.82		-0.81	-0.78	-0.79
Total Current Assets	1.0	-0.82	0.77	0.65	0.61	-0.38	-0.81	-0.93	-0.78	-0.94	0.94	-0.8	-0.58	-0.58	1.0	-0.75	-0.31	-0.82	0.79	0.9	-0.3	0.61	-0.81		0.74	1.0
Capital Stock	0.74	-0.78	0.8	0.74	0.85	0.29	-0.78	-0.64	-0.73	-0.74	0.64	-0.79	-0.66	-0.66	0.74	-0.98	-0.76	-0.78	0.65	0.55	-0.75	0.85	-0.78	0.74		0.73
Net Working Capital	1.0	-0.81	0.75	0.62	0.61	-0.39	-0.79	-0.94	-0.76	-0.94	0.95	-0.79	-0.57	-0.57	1.0	-0.74	-0.31	-0.81	0.78	0.91	-0.29	0.61	-0.79	1.0	0.73

Click cells to compare fundamentals

Sagimet Biosciences Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sagimet Stock Analysis

When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sagimet Current Deferred Revenue vs Net Invested Capital Analysis

Current Deferred Revenue vs Net Invested Capital

Current Deferred Revenue vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Invested Capital

Sagimet Biosciences fundamental ratios Correlations

Sagimet Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Sagimet Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total

Other Stockholder Equity	- 0.99	Net Debt
Capital Stock	- 0.98	Common Stock Shares Outstanding
Cash	- 0.97	Net Debt
Net Invested Capital	- 0.94	Non Current Liabilities Total
Net Working Capital	- 0.94	Accounts Payable
Total Current Assets	- 0.94	Accounts Payable